Alkylating agents
HIPEC for Recurrent Ovarian Cancer
This trial is comparing the effectiveness of two different treatments for ovarian, primary peritoneal, or fallopian tube cancer that has come back. One treatment is surgery to remove as much of the cancer as possible, followed by a single dose of chemotherapy given through the abdomen directly to the area where the cancer was. The other treatment is 6 cycles of standard chemotherapy given intravenously.
Cancer Vaccine
Oregovomab + Niraparib for Ovarian Cancer
This trial tests a new treatment combining two drugs, oregovomab and niraparib, for patients with ovarian cancer that has come back but still responds to certain chemotherapy. The treatment aims to help the immune system better recognize and destroy cancer cells while also preventing the cancer cells from fixing themselves. About 10 patients will be treated and monitored for safety and effectiveness. Niraparib is approved for use in patients with newly-diagnosed or recurrent ovarian cancer.
Monoclonal Antibodies
Pembrolizumab + Bevacizumab for Ovarian Cancer
This trial is testing a new immunotherapy treatment for ovarian cancer. The treatment includes two monoclonal antibodies and a drug that stimulates the immune system. The goal is to shrink tumors and improve quality of life for patients with ovarian cancer.
mTORC1/2 Inhibitor
mTOR/AKT Inhibitors for Endometrial and Ovarian Cancer
This trial is testing the side effects and best dose of two different drug combinations in treating patients with recurrent endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer.
Popular Filters
Trials for Ovarian Cancer Patients
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Platinum-based Chemotherapy
Chemo-Immunotherapy for Recurrent Ovarian Cancer
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given through IV and intraperitoneal (IP) infusion. The trial will evaluate the effectiveness and safety of the new combination.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
Trials for SOC Patients
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Platinum-based Chemotherapy
Chemo-Immunotherapy for Recurrent Ovarian Cancer
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given through IV and intraperitoneal (IP) infusion. The trial will evaluate the effectiveness and safety of the new combination.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
Trials for Metastatic Patients
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
Alkylating agents
Chemoimmunotherapy + Vaccines for Recurrent Ovarian Cancer
This trial will test a treatment plan for advanced ovarian cancer patients. They will first receive a combination of drugs directly into the abdominal cavity and through the vein. Then, they will receive another treatment containing a
Epigenetic Modulator
CPI-0209 + Carboplatin for Ovarian Cancer
This trial is testing a new drug, CPI-0209, combined with chemotherapy in patients with recurrent ovarian cancer. The goal is to see if CPI-0209 can make chemotherapy work better and prevent the cancer from returning by blocking resistance and spread.
Trials for BRCA Positive Patients
PARP Inhibitor and ATR Inhibitor
ATR Inhibitor + PARP Inhibitor for Ovarian Cancer
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given to women who have had the disease come back after treatment. The study will look at if the combination is safe and works well.
PARP Inhibitor
Cediranib + Olaparib for Ovarian Cancer
This study is evaluating whether a drug called olaparib and a drug called cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent).
Epigenetic Modulator
CPI-0209 + Carboplatin for Ovarian Cancer
This trial is testing a new drug, CPI-0209, combined with chemotherapy in patients with recurrent ovarian cancer. The goal is to see if CPI-0209 can make chemotherapy work better and prevent the cancer from returning by blocking resistance and spread.
CAR T-cell Therapy
FSHR-Targeted T Cell Therapy for Ovarian Cancer
This trial is testing a new treatment that uses a patient's own modified immune cells to target and kill cancer cells. It focuses on patients whose ovarian, fallopian tube, or primary peritoneal cancer has come back or hasn't responded to other treatments.
Phase 3 Trials
Monoclonal Antibodies
Pembrolizumab + Paclitaxel +/- Bevacizumab for Ovarian Cancer
This trial is testing a new cancer treatment combining two drugs, pembrolizumab and paclitaxel, with or without bevacizumab. The goal is to see if this new combination can prolong the amount of time until the cancer progresses, compared to the current standard treatment.
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
PARP Inhibitor
Cediranib + Olaparib for Recurrent Ovarian Cancer
This trial is testing two oral drugs, cediranib maleate and olaparib, alone or together, against standard chemotherapy for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to previous treatments. The drugs aim to block enzymes needed for cancer cell growth. The goal is to see if these drugs are more effective than standard chemotherapy.
Trials With No Placebo
CDK4/6 Inhibitor
Ribociclib + Belinostat for Breast Cancer
This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
Platinum-based Chemotherapy
Chemo-Immunotherapy for Recurrent Ovarian Cancer
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given through IV and intraperitoneal (IP) infusion. The trial will evaluate the effectiveness and safety of the new combination.
Monoclonal Antibodies
REGN4018 + Cemiplimab for Ovarian Cancer
This trial is studying REGN4018, given alone or together with cemiplimab, to see how well it works in treating patients with solid tumors that have spread (metastatic) or cannot be removed by surgery (unresectable).
PARP Inhibitor and ATR Inhibitor
ATR Inhibitor + PARP Inhibitor for Ovarian Cancer
This trial will test a new combination of drugs to treat ovarian cancer. The drugs will be given to women who have had the disease come back after treatment. The study will look at if the combination is safe and works well.
View More Related Trials
Frequently Asked Questions
Introduction to recurrent ovarian cancer
What are the top hospitals conducting recurrent ovarian cancer research?
When it comes to combatting recurrent ovarian cancer, several remarkable hospitals are leading the way with their dedication to innovative clinical trials. One such institution is the M D Anderson Cancer Center located in Houston. With 11 active trials specifically targeting recurrent ovarian cancer, this center focuses on finding new treatments and potential cures for this challenging condition. Meanwhile, the University of Colorado Hospital in Aurora is also making significant strides with nine ongoing trials dedicated to recurrent ovarian cancer patients. These hospitals are at the forefront of pioneering research efforts and aim to improve outcomes for those affected by this disease.
In addition to these centers, Mayo Clinic in Rochester has eight active clinical trials underway that directly address recurrent ovarian cancer. This renowned clinic's commitment towards finding better therapies and understanding the intricacies of this illness cannot be understated. Similarly, the University of Chicago Comprehensive Cancer Center prides itself on its eight current clinical trials focused solely on combating recurrent ovarian cancer. Their expertise and dedication make them a formidable force in advancing knowledge about this complex disease.
Lastly, we have the University of Pittsburgh Cancer Institute (UPCI) situated in Pittsburgh—a hospital that shares equal passion among other top institutions when it comes to fighting against recurrence from ovarian cancers—boasting eight active clinical trials targeting this specific aspect as well.
Although these hospitals may not have conducted any previous studies devoted explicitly to recurring cases yet due perhaps being relatively young or recent additions within domain regardless their exceptional focus today signifies great promise for progress moving forward into future years ahead- granting renewed hope countless patients across nation can rely upon!
Which are the best cities for recurrent ovarian cancer clinical trials?
When it comes to recurrent ovarian cancer clinical trials, several cities have emerged as leading hubs for research and advancement. Anchorage, Alaska takes the lead with 43 active trials investigating treatments like Bevacizumab, epacadostat, pembrolizumab, and Tazemetostat. Denver, Colorado closely follows with 42 ongoing studies focusing on similar interventions including Bevacizumab, epacadostat, pembrolizumab, and Nivolumab. Chicago in Illinois boasts 24 active trials examining pharmacological studies such as Paclitaxel and REGN5668. Additionally, Aurora in Colorado offers another 24 ongoing trials exploring options like Bevacizumab and NovoTTF-100L(O). Lastly, Los Angeles in California contributes significantly to the field with 23 active trials that delve into promising treatments involving Bevacizumab, Paclitaxel ,and targeted therapies for MET exon 14 deletion/mutations. These cities represent hotspots of research where individuals battling recurrent ovarian cancer can access cutting-edge clinical trials offering hope for improved outcomes.
Which are the top treatments for recurrent ovarian cancer being explored in clinical trials?
When it comes to recurrent ovarian cancer, clinical trials are shedding light on several promising treatments. Leading the pack is niraparib, a drug currently being explored in six active trials dedicated to tackling this challenging disease. Another contender making waves is olaparib, with four ongoing clinical trials focused specifically on recurrent ovarian cancer. Rucaparib also shows promise with its involvement in three active studies for this condition. These innovative therapies offer hope for patients as researchers strive to find effective solutions against recurrent ovarian cancer.
What are the most recent clinical trials for recurrent ovarian cancer?
Exciting advancements are being made in the field of recurrent ovarian cancer, with recent clinical trials offering potential breakthroughs for patients. One notable trial explores a combination treatment approach involving apheresis, FRalphaDC, and pembrolizumab. Another study focuses on the efficacy of CPI-0209 (150 mg) alongside carboplatin. Additionally, pembrolizumab has shown promise as a standalone treatment option for recurrent ovarian cancer. Furthermore, Arm I investigates the effectiveness of selumetinib and olaparib in combating this form of cancer. Lastly, EAY191-E5 Cohort II examines sotorasib's impact on recurrent ovarian cancer. These trials offer hope for improved outcomes and enhanced quality of life for individuals battling this challenging disease.
What recurrent ovarian cancer clinical trials were recently completed?
Several clinical trials investigating new treatments for recurrent ovarian cancer have recently concluded, presenting promising prospects in the fight against this challenging disease. Notably, a trial sponsored by the National Cancer Institute (NCI) centered on the study of Olaparib and Cediranib combination therapy reached completion in May 2021. Additionally, another NCI-sponsored trial exploring Rucaparib as maintenance therapy concluded in July 2021. These significant developments highlight the ongoing efforts to advance treatment options for patients with recurrent ovarian cancer and bring hope for improved outcomes in the future.